Inhibition of Experimental Abdominal Aortic Aneurysm in the Rat by Use of Decoy Oligodeoxynucleotides Suppressing Activity of Nuclear Factor κB and ets Transcription Factors

Circulation

Volumn 109, Issue 1, 2004, Pages 132-138

  Nakashima, Hideki ^a   Aoki, Motokuni ^a   Miyake, Takashi ^a   Kawasaki, Tomio ^e   Iwai, Masahiro ^a,b   Jo, Nobuo ^a   Oishi, Masako ^a   Kataoka, Kazusaburo ^a   Ohgi, Shigetsugu ^c   Ogihara, Toshio ^a   Kaneda, Yasufumi ^a   Morishita, Ryuichi ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

Aneurysm; Aorta; Gene therapy; Inflammation; Metalloproteinase

Indexed keywords

CHIMERIC DECOY OLIGODEOXYNUCLEOTIDE; CHIMERIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELASTIC FIBER; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE REPRESSION; GENE THERAPY; GENETIC TRANSFECTION; INFLAMMATION; MACROPHAGE MIGRATION; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; TREATMENT OUTCOME;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; MALE; MATRIX METALLOPROTEINASES; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RATS; RATS, WISTAR; TRANSCRIPTION FACTORS;

EID: 0347988101     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000105725.61763.A2     Document Type: Article

References (39)

1. Newman KM, Jean-Claude J, Li H, et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 1994;20:814-820.
2. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995;96:318-326.
3. Petrinec D, Liao S, Holmes DR. et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336-346.
4. Knox JB, Sukhova GK, Whittemore AD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 1997;95:205-212.
5. Tamarina NA, McMillan WD, Shively VP, et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery. 1997;122:264-272.
6. McMillan WD, Tamarina NA, Cipollone M, et al. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation. 1997;96:2228-2232.
7. Treharne GD, Boyle JR, Goodall S, et al. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg. 1999;86:1053-1058.
8. Moore G, Liao S, Curci JA, et al. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg. 1999;29:522-532.
9. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
10. Boyle JR, McDermott E, Crowther M, et al. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg. 1998;27:354-361.
11. Bond M, Baker AH, Newby AC. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun. 1999;264:561-567.
12. Takeshita H, Yoshizaki T, Miller WE, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol. 1999;73:5548-5555.
13. Kim H, Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2000;269:401-405.
14. Campbell SE, Nasir L, Argyle DJ. et al. Molecular cloning and characterization of canine metalloproteinase-9 gene promoter. Gene. 2001;273: 81-87.
15. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol. 2002;22:765-771.
16. Vandenbunder B, Wernert N, Queva C, et al. Does the transcription factor c-etsl take part in the regulation of angiogenesis and tumor invasion? Folia Biol Praha. 1994;40:301-313.
17. Nerlov C, Rorth P, Blasi F, et al. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene. 1991;6:1583-1592.
18. Gum R, Lengyel E, Juarez J, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672-10680.
19. Watabe T, Yoshida K, Shindoh M, et al. The ets-1 and ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer. 1998;77:128-137.
20. Holmes DR, Petrinec D, Wester W, et al. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res. 1996;63: 305-309.
21. Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001;33:1057-1064.
22. Morishita R, Sugimoto J, Aoki M, et al. In vivo transfection of cis element "decoy" against NFkB binding site prevented myocardial infarction as gene therapy. Nat Med. 1997;3:894-899.
23. Aoki M, Morishita R, Taniyama Y, et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 2000;7:417-427.
24. Aoki M, Morishita R, Higaki J, et al. Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and β-galactosidase gene in non-infarcted area, but not myocardial infarcted area. Gene Ther. 1997;4:120-127.
25. Aoki M, Morishita R, Higaki J, et al. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. Biochem Biophys Res Commun. 1997;231:540-545.
26. Neish AS, Williams AJ, Palmer HJ, et al. Functional analysis of human vascular cell adhesion molecule 1 promoter. J Exp Med. 1992;176: 1583-1593.
27. O'Connell J, Willenbrock F, Docherty J, et al. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem. 1994;269:14967-14973.
28. Mason DP, Kenagy RD, Hasenstab D, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999;85: 1179-1185.
29. Baxter BT, McGee GS, Shively VP, et al. Elastin content, cross-links, and mRNA in normal and aneurysmal human aorta. J Vasc Surg. 1992;16: 192-200.
30. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg. 1994;81:935-941.
31. Anidjar S, Kieffer E. Pathogenesis of acquired aneurysms of the abdominal aorta. Ann Vasc Surg. 1992;6:298-305.
32. Brophy CM, Reilly JM, Smith GJ, et al. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg. 1991;5: 229-233.
33. Freestone T. Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
34. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110: 625-632.
35. Yamashita A, Noma T, Nakazawa A, et al. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J Surg. 2001;25:259-265.
36. Satta J, Laurila A, Paakko P, et al. Chronic inflammation and elastin degradafion in abdominal aortic aneurysm disease: an immunohistochemical and electron microscopic study. Eur J Vasc Endovasc Surg. 1998;15:313-319.
37. Petersen E, Gineitis A, Wagberg F, et al. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms: relation to size and rupture. Eur J Vasc Endovasc Surg. 2000;20:457-461.
38. Lindholt JS, Vammen S, Fasting H, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms: a preliminary study. Eur J Vasc Endovasc Surg. 2000; 20:281-285.
39. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.